Ironwood Pharmaceuticals Inc (IRWD)

Name: Ironwood Pharmaceuticals Inc (IRWD) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

SEC name IRONWOOD PHARMACEUTICALS INC · CIK 0001446847 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, Ironwood Pharmaceuticals Inc reported revenue of $296.15M. Revenue fell 15.7% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $389.32M.

Key ratios (year ended 2025-12-31)

33.3%

Operating margin

8.1%

Net margin

-15.7%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-16

Headquarters locality: Cambridge · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	$389.32M	$296.15M	$351.41M	$442.74M	$410.60M	$413.75M	$389.52M	$428.41M	$346.64M	$298.28M	$273.96M
Cost of Revenue	n/a	n/a	n/a	n/a	n/a	n/a	$3.14M	$23.88M	$32.75M	$19.10M	$1.87M
Gross Profit (computed)	n/a	n/a	n/a	n/a	n/a	n/a	n/a	$404.54M	$313.89M	$279.18M	n/a
R&D Expense	$88.69M	$95.14M	$111.42M	$116.08M	$44.27M	$70.41M	$88.06M	$115.04M	$101.06M	$88.14M	$139.49M
Operating Income	$234.17M	$98.50M	$93.12M	-$945.43M	$250.34M	$232.26M	$142.94M	$120.12M	-$150.67M	-$15.36M	-$51.87M
Depreciation & Amortization	n/a	$1.10M	$1.20M	$1.20M	$1.40M	$1.50M	$2.30M	$5.60M	$3.90M	$6.40M	$10.28M
EBITDA	n/a	$99.60M	$94.32M	-$944.23M	$251.74M	$233.76M	$145.24M	$125.72M	-$146.77M	-$8.96M	-$41.59M
Net Income	$129.87M	$24.02M	$880.0K	-$1.03B	$175.06M	$528.45M	$106.18M	$21.50M	-$282.37M	-$116.94M	-$81.71M
EPS (Diluted)	n/a	$0.15	$0.01	-$6.45	$0.96	$3.21	$0.66	$0.14	-$1.85	n/a	n/a
Total Assets	$285.13M	$396.90M	$350.91M	$471.07M	$1.10B	$1.13B	$559.24M	$402.75M	$332.05M	$605.67M	$709.82M
Long-Term Debt	n/a	n/a	n/a	n/a	$396.25M	$454.19M	$430.26M	n/a	n/a	n/a	n/a
Shareholders' Equity	-$161.84M	-$261.83M	-$301.33M	-$346.30M	$652.38M	$605.91M	$62.64M	-$93.25M	-$196.37M	$9.85M	$66.72M
Cash & Equivalents	$79.13M	$215.46M	$88.56M	$92.15M	$656.20M	$620.13M	$362.56M	$177.02M	$173.17M	$125.74M	$54.00M
Operating Cash Flow	$185.56M	$127.04M	$103.55M	$183.43M	$273.76M	$261.89M	$168.84M	$10.72M	-$70.88M	-$100.75M	-$25.93M
Capital Expenditures	n/a	$34.0K	$142.0K	$273.0K	$136.0K	$265.0K	$1.84M	$7.19M	$351.0K	$2.80M	$4.21M
Free Cash Flow	n/a	$127.01M	$103.41M	$183.15M	$273.63M	$261.63M	$166.99M	$3.54M	-$71.23M	-$103.56M	-$30.14M
Share Repurchases	n/a	n/a	n/a	n/a	$126.39M	$24.13M	n/a	n/a	n/a	n/a	n/a
Shares Outstanding	165.24M	163.06M	160.21M	156.35M	154.03M	162.04M	160.62M	157.54M	154.41M	n/a	n/a
Weighted Average Diluted Shares	n/a	162.98M	160.08M	155.44M	186.31M	164.42M	160.66M	156.02M	152.63M	n/a	n/a
EPS (Basic)	n/a	$0.15	$0.01	-$6.45	$1.13	$3.26	$0.67	$0.14	-$1.85	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView